Compare TR & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | BLLN |
|---|---|---|
| Founded | 1896 | 2016 |
| Country | United States | United States |
| Employees | 2100 | 713 |
| Industry | Specialty Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.9B |
| IPO Year | N/A | N/A |
| Metric | TR | BLLN |
|---|---|---|
| Price | $42.54 | $75.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $126.71 |
| AVG Volume (30 Days) | 82.5K | ★ 380.5K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | N/A | $30.14 |
| P/E Ratio | $32.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.59 | $61.96 |
| 52 Week High | $45.06 | $138.70 |
| Indicator | TR | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 43.65 |
| Support Level | $40.07 | $64.99 |
| Resistance Level | $43.37 | $83.20 |
| Average True Range (ATR) | 1.25 | 6.30 |
| MACD | -0.10 | -1.22 |
| Stochastic Oscillator | 51.30 | 18.08 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.